CheckMate-9DW: Complete Statistical Analysis of Nivolumab and Ipilimumab in Advanced Hepatocellular Carcinoma

1. Trial at a Glance

CheckMate-9DW was a completed phase 3 randomized trial evaluating nivolumab in combination with ipilimumab in participants with advanced hepatocellular carcinoma.

2. Clinical Question

3. Trial Design

4. Endpoints

5. Planned Analysis

The ClinicalTrials.gov record identifies Overall Survival as the primary endpoint. No posted statistical analyses or numerical efficacy results are reported in the registry record.

For an overall survival endpoint, the typical statistical framework is a time-to-event analysis using methods such as Kaplan-Meier estimation, comparison of survival distributions between randomized groups, and estimation of relative treatment effects using survival models. Interpretation depends on the prespecified analysis plan, censoring rules, and the handling of subsequent therapies.

6. Statistical Methodology

Time-to-event analysis

Overall survival measures time from a defined starting point until death from any cause. Patients who have not experienced the event by the analysis cutoff are generally treated as censored observations.

Kaplan-Meier estimation

Kaplan-Meier methods estimate survival probabilities over time while accounting for incomplete follow-up. The resulting survival curve describes the observed pattern of events and censoring.

Hazard ratios

If a proportional-hazards model is prespecified, a hazard ratio summarizes the relative event rate between groups over the analyzed follow-up. It is not the same as the probability that an individual patient experiences an event.

7. Statistical Methods Explained

Why is Overall Survival analyzed as a time-to-event endpoint?

Because participants may have different follow-up durations, survival methods incorporate both observed events and censored follow-up information.

What does randomization contribute statistically?

Randomization helps balance known and unknown factors between treatment groups, allowing the comparison to estimate treatment effects under the trial design.

Why is censoring important?

Censoring allows participants with incomplete event follow-up to contribute available information without assuming their future outcomes.

Why are confidence intervals important?

Confidence intervals describe uncertainty around an estimated treatment effect and provide information beyond whether a statistical threshold was crossed.

Why must the analysis plan be prespecified?

Prespecified methods help control bias and distinguish confirmatory analyses from exploratory evaluations.

8. Limitations

• No posted statistical analyses: The registry record does not report numerical endpoint analyses.
• Endpoint interpretation: Overall survival reflects the complete treatment pathway after randomization, including later treatments that may occur during follow-up.
• Open-label design: The registry reports masking as none, which can affect aspects of trial conduct and assessment depending on the endpoint.
• Generalizability: Applicability depends on the enrolled trial population and eligibility criteria.

9. Why This Trial Matters Statistically

10. Related Tutorials

11. Related Calculators

12. Sources

• ClinicalTrials.gov: NCT04039607
• PubMed: PubMed record
• PubMed: PubMed record
• PubMed: PubMed record